HRP20020977B1 - Orto-supstituirani amidi antranilne kiseline i njihova upotreba kao farmaceutskih sredstava - Google Patents

Orto-supstituirani amidi antranilne kiseline i njihova upotreba kao farmaceutskih sredstava

Info

Publication number
HRP20020977B1
HRP20020977B1 HR20020977A HRP20020977A HRP20020977B1 HR P20020977 B1 HRP20020977 B1 HR P20020977B1 HR 20020977 A HR20020977 A HR 20020977A HR P20020977 A HRP20020977 A HR P20020977A HR P20020977 B1 HRP20020977 B1 HR P20020977B1
Authority
HR
Croatia
Prior art keywords
ortho
substituted
acid amides
chlorine
medicinal products
Prior art date
Application number
HR20020977A
Other languages
English (en)
Croatian (hr)
Inventor
Krueger Martin
Huth Andreas
Petrov Orlin
Seidelmann Dieter
Thierauch Karl-Heinz
Haberey Martin
Menrad Andreas
Ernst Alexander
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HRP20020977A2 publication Critical patent/HRP20020977A2/xx
Publication of HRP20020977B1 publication Critical patent/HRP20020977B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20020977A 2000-05-09 2001-05-08 Orto-supstituirani amidi antranilne kiseline i njihova upotreba kao farmaceutskih sredstava HRP20020977B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10023486A DE10023486C1 (de) 2000-05-09 2000-05-09 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
PCT/EP2001/005214 WO2001085719A1 (de) 2000-05-09 2001-05-08 Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
HRP20020977A2 HRP20020977A2 (en) 2005-02-28
HRP20020977B1 true HRP20020977B1 (hr) 2008-05-31

Family

ID=7641923

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020977A HRP20020977B1 (hr) 2000-05-09 2001-05-08 Orto-supstituirani amidi antranilne kiseline i njihova upotreba kao farmaceutskih sredstava

Country Status (30)

Country Link
US (2) US7081468B2 (da)
EP (1) EP1280799B1 (da)
JP (1) JP2003532725A (da)
KR (1) KR20020094024A (da)
CN (1) CN1237062C (da)
AT (1) ATE258174T1 (da)
AU (2) AU7400101A (da)
BG (1) BG107261A (da)
BR (1) BR0110621A (da)
CA (1) CA2407852A1 (da)
CZ (1) CZ20023677A3 (da)
DE (2) DE10023486C1 (da)
DK (1) DK1280799T3 (da)
EE (1) EE04938B1 (da)
ES (1) ES2214424T3 (da)
HR (1) HRP20020977B1 (da)
HU (1) HUP0301954A2 (da)
IL (2) IL152578A0 (da)
MX (1) MXPA02010915A (da)
NO (1) NO323541B1 (da)
NZ (1) NZ521700A (da)
PL (1) PL358204A1 (da)
PT (1) PT1280799E (da)
RU (1) RU2264399C2 (da)
SK (1) SK15882002A3 (da)
TR (1) TR200400912T4 (da)
UA (1) UA73187C2 (da)
WO (1) WO2001085719A1 (da)
YU (1) YU82702A (da)
ZA (1) ZA200209896B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
CA2493026C (en) * 2002-07-31 2011-05-24 Bayer Schering Pharma Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
JP2006526660A (ja) * 2003-06-05 2006-11-24 バーテックス ファーマシューティカルズ インコーポレイテッド Vr1レセプターのモジュレーター
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
ATE546452T1 (de) 2003-09-23 2012-03-15 Vertex Pharma Pyrazolopyrrolderivate als proteinkinaseinhibitoren
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US7427390B2 (en) * 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
DE102004011720B4 (de) * 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
BRPI0619208A2 (pt) 2005-11-30 2011-09-20 Astellas Pharma Inc derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
FI3805233T3 (fi) 2014-01-13 2024-04-17 Aurigene Oncology Ltd N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
JP2017518348A (ja) * 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited Irak4阻害剤としての置換インダゾール化合物
DK3600270T3 (da) 2017-03-31 2023-07-10 Aurigene Oncology Ltd Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
CA3079628A1 (en) 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders
KR20240004476A (ko) 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
FR2689508B1 (fr) * 1992-04-01 1994-06-17 Fournier Ind & Sante Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
MXPA03010099A (es) * 2001-05-08 2004-03-10 Schering Ag Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3.
US20040039019A1 (en) * 2002-06-19 2004-02-26 Schering Ag Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
US7517894B2 (en) * 2002-07-31 2009-04-14 Bayer Schering Pharma Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
NZ553260A (en) * 2004-07-19 2010-12-24 Thia Medica As Composition comprising protein material and non-oxidizable fatty acid entities
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US20060266770A1 (en) * 2005-05-26 2006-11-30 Fitzgerald Robert M Portable dispensers comprising a mobile dispenser and mobile storage cartridge

Also Published As

Publication number Publication date
EE04938B1 (et) 2007-12-17
JP2003532725A (ja) 2003-11-05
CZ20023677A3 (cs) 2003-02-12
PT1280799E (pt) 2004-06-30
AU7400101A (en) 2001-11-20
WO2001085719A1 (de) 2001-11-15
IL152578A (en) 2008-11-03
BR0110621A (pt) 2003-03-25
NO20025358D0 (no) 2002-11-08
BG107261A (bg) 2003-06-30
ATE258174T1 (de) 2004-02-15
IL152578A0 (en) 2003-05-29
EE200200625A (et) 2004-04-15
WO2001085719A9 (de) 2001-12-27
NO323541B1 (no) 2007-06-11
US20040102441A1 (en) 2004-05-27
YU82702A (sh) 2006-05-25
HUP0301954A2 (hu) 2003-09-29
HK1056728A1 (en) 2004-02-27
PL358204A1 (en) 2004-08-09
KR20020094024A (ko) 2002-12-16
ES2214424T3 (es) 2004-09-16
AU2001274001B2 (en) 2007-01-18
CN1427837A (zh) 2003-07-02
NZ521700A (en) 2005-09-30
EP1280799A1 (de) 2003-02-05
DE10023486C1 (de) 2002-03-14
MXPA02010915A (es) 2003-07-14
NO20025358L (no) 2002-11-08
UA73187C2 (en) 2005-06-15
US20060014747A1 (en) 2006-01-19
CA2407852A1 (en) 2001-11-15
SK15882002A3 (sk) 2003-08-05
CN1237062C (zh) 2006-01-18
HRP20020977A2 (en) 2005-02-28
TR200400912T4 (tr) 2004-07-21
RU2264399C2 (ru) 2005-11-20
ZA200209896B (en) 2004-03-05
US7081468B2 (en) 2006-07-25
DK1280799T3 (da) 2004-05-10
EP1280799B1 (de) 2004-01-21
DE50101364D1 (de) 2004-02-26

Similar Documents

Publication Publication Date Title
HRP20020977B1 (hr) Orto-supstituirani amidi antranilne kiseline i njihova upotreba kao farmaceutskih sredstava
HRP20030278B1 (en) Novel anticholinergic agents that can be used as medicaments and method for the production thereof
PT74390A (fr) Nouveaux acides 2-<4-(diphenylmethyl)-1-piperazinyl>-acetiques et leurs amides leurs procedes de preparation et compositions therapeutiques
NI200500106A (es) Derivados de dihidropiranoindol-3,4-diona sustituidos y derivados de 2-hidroxi-metilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
MA31685B1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
HRP20020617B1 (en) Substituted oxazolidinones and ther use in the field of blood coagulation
CO4920234A1 (es) Derivados de acidos arilsulfonilaminomidroxamicos
HRP20161547T1 (hr) Derivati 5-fluor-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku skupinu
ME02698B (me) Inhibitori neprilizina
HRP20040178B1 (hr) Derivati piperidina kao antagonisti nmda receptora
ATE316961T1 (de) Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
CA2446326A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
NO974843D0 (no) Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser
YU48446B (sh) Postupak za dobijanje novih derivata 1-(cikloheksil)-4- aril-4-piperidinkarboksilne kiseline
CO4950515A1 (es) Nuevos derivados de la quinolina para uso medicinal
IS2194B (is) Efnasambönd sem innihalda píperasín sem eru gagnleg til meðhöndlunar á sársauka
HRP20090264T1 (hr) Derivati fenil-piperazin metanona
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
ES356131A1 (es) Procedimiento de preparacion de nuevas amidinas aromaticas n-sustituidas.
IE45556L (en) 2-[n-(cycloalkylmethyl)-n-(phenyl)-amino]-2- imidazoline¹derivatives
Zask et al. Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
AR027782A1 (es) Nuevo procedimiento para la sintesis de los esteres de n-[(s)-1-carboxibutil]-(s)-alanina y su aplicacion en la sintesis del perindoprilo
DE69402935D1 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080417

Year of fee payment: 8

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

PBON Lapse due to non-payment of renewal fee

Effective date: 20090509